transmembrane protein 33Genealiases: 1600019D15Rik · Pom33 · SHINC-3 · SHINC3
Q-omics provides the consensus-scored TMEM33 profile across patient tissues and cancer cell-line models. TMEM33 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, TMEM33 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, TMEM33 protein abundance shows 24,264 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, HNSC, and GBM as cancer lineages where TMEM33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM33 survival associations across molecular data types. TMEM33 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM33 RNA expression–survival associations across cancer types. High TMEM33 expression shows unfavorable associations in CESC, UVM, HNSC and KIRP, but favorable associations in READ and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for TMEM33 RNA expression.
This table summarizes TMEM33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM33 shows higher tumor expression in HNSC, BLCA, STAD, LUAD, BRCA and LIHC. The HNSC box plot shows higher TMEM33 RNA expression in tumor versus normal tissue (log2 FC = +0.875, t-test p < 0.001).
This table shows molecular features associated with TMEM33 in patient tissues and cancer cell lines. In patient samples, TMEM33 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
